MANUFACTURING OF AYUSH DRUGS
Issued by AYUSH
Read or download the official PDF of this gazette notification issued by the AYUSH on 7th August 2026. Classified under Press Release.
Executive Summary & Key Takeaways
Executive Summary The Ministry of Ayush is implementing a comprehensive Pharmacovigilance Programme to monitor the safety of Ayush medicines and curb misleading advertisements. Key initiatives include the launch of the "Ayush Suraksha" portal in 2025 for tracking adverse drug reactions and objectionable claims, and the enforcement of the Drugs & Magic Remedies (Objectionable Advertisements) Act, 1954. Between 2023 and 2025, the Ministry received 34,061 complaints regarding misleading advertisements, prompting heightened regulatory actions and public awareness campaigns.
Key Points / Main Content
Pharmacovigilance Framework and Monitoring
- Three-Tier Network: The programme operates through a National Pharmacovigilance Centre (NPvCC), five Intermediary Centres (IPvCs), and 97 Peripheral Centres (PPvCs).
- AOGUSY Integration: The pharmacovigilance initiative was incorporated under the Ayush Oushadhi Gunavatta Evam Uttpadan Samvardhan Yojana in 2021.
- Safety Monitoring: The system monitors suspected adverse drug reactions (ADRs) to promote the safe and rational use of Ayush medicines.
Regulatory and Legal Enforcement
- Legislative Authority: States and UTs are empowered under Section 8 of the Drugs & Magic Remedies (Objectionable Advertisements) Act, 1954, to prohibit exaggerated medicinal claims in print and electronic media.
- Digital Regulation: The Coordinator of the NPvCC is notified as the nodal officer under the Information Technology Act, 2000, to issue notices to intermediaries regarding unlawful online content.
- Homeopathy Oversight: The Board of Ethics and Registration for Homoeopathy (BERH) issues circulars to curb unsubstantiated information regarding homeopathic treatments.
Digital Tools and Public Outreach
- Ayush Suraksha Portal: An IT-enabled portal launched in 2025 to track and manage Misleading Advertisements (MLAs) and ADRs.
- Awareness Campaigns: 4,165 awareness programmes have been conducted for professionals and the public, reaching 371,477 participants.
- Public Notices: Formal notices were issued on 08.10.2024 and 24.08.2025 in 100 leading newspapers across multiple languages to warn the public against misleading advertisements.
Statistical Trends (2023–2025)
- Rising Complaints: Reported misleading advertisements increased from 7,771 in 2023 to 16,129 in 2025.
- State-Level Action: Significant numbers of advertisements were reported in states like Tamil Nadu (3,079) and Madhya Pradesh (1,115), with varying degrees of action taken by local authorities.
Impact Analysis
Ministry of Ayush / Central Government Impact Responsible for establishing the regulatory framework, notifying nodal officers, and providing directions to State Licensing Authorities (SLAs). Action Required Continue monitoring via the three-tier pharmacovigilance network and issue advisories to strengthen the regulatory framework.
State/UT Governments and State Licensing Authorities (SLAs) Impact Empowered to notify enforcement officers and regulate misleading advertisements appearing in their respective jurisdictions. Action Required Enforce provisions of the Drugs & Magic Remedies Act and take action against reported advertisements on the Ayush Suraksha portal.
Digital Intermediaries Impact Subject to legal notices if their computer resources are used to host or communicate data that violates Ayush drug regulations. Action Required Comply with notices issued by the NPvCC nodal officer regarding the removal or regulation of objectionable information.
Ayush Professionals and General Public Impact Beneficiaries of awareness programmes; they serve as the primary source for reporting adverse reactions and misleading claims. Action Required Avoid patronizing misleading advertisements and report suspected adverse reactions or objectionable claims via the Ayush Suraksha portal.